It has been reported that the expression levels of FOSL1 in drug-resistant breast cancer cells, specifically MCF-7/ADR and MDA-MB-231/ADR, noticeably increase, leading to the induction of resistance to doxorubicin both in vitro and in vivo. The gene discussed is FOSL1; the disease is breast carcinoma.